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Abstract
Background: The application of serological methods in HIV/AIDS routine surveillance systems to identify persons
with recently acquired HIV infection has been proposed as a tool which may provide an accurate description of
the current transmission patterns of HIV. Using the information about recent infection it is possible to estimate HIV
incidence, according to the model proposed by Karon et al. in 2008, that accounts for the effect of testing
practices on the number of persons detected as recently infected.
Methods: We used data from HIV/AIDS surveillance in the period 2004-2008 to identify newly diagnosed persons.
These were classified with recent/non-recent infection on the basis of an avidity index result, or laboratory
evidence of recently acquired infection (i.e., previous documented negative HIV test within 6 months; or presence
of HIV RNA or p24 antigen with simultaneous negative/indeterminate HIV antibody test). Multiple imputation was
used to impute missing information. The incidence estimate was obtained as the number of persons detected as
recently infected divided by the estimated probability of detection. Estimates were stratified by calendar year,
transmission category, gender and nationality.
Results: During the period considered 3,633 new HIV diagnoses were reported to the regional surveillance system.
Applying the model, we estimated that in 2004-2008 there were 5,465 new infections (95%CI: 4,538-6,461);
stratifying by transmission category, the estimated number of infections was 2,599 among heterosexual contacts,
2,208 among men-who-have-sex-with-men, and 763 among injecting-drug-users. In 2008 there were 952 (625-
1,229) new HIV infections (incidence of 19.9 per 100,000 person-years). In 2008, for men-who-have-sex-with-men
(691 per 100,000 person-years) and injecting drug users (577 per 100,000 person-years) the incidence remained
comparatively high with respect to the general population, although a decreasing pattern during 2004-2008 was
observed for injecting-drug-users.
Conclusions: These estimates suggest that the transmission of HIV infection in Lazio remains frequent and men-
who-have-sex-with men and injecting-drug-users are still greatly affected although the majority of new infections
occurs among heterosexual individuals.
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Estimating HIV incidence is essential for monitoring the
evolution of the epidemic and evaluating the effective-
ness of prevention efforts. However, providing accurate
estimates of HIV incidence is a complex task. Measuring
the seroconversion rate in cohort studies or repeated
serosurveys is expensive and at best reveal incidence in
high-risk groups [1] while routine surveillance systems
record new HIV diagnoses and not new infections [2].
The application of new laboratory techniques in HIV/
AIDS routine surveillance systems to identify persons
with recently acquired HIV infection has been proposed
as a tool which may provide an accurate description of
the current transmission patterns of HIV. These techni-
ques are based on serological tests, usually defined as
tests for recent infection (TRI), which use different algo-
rithms to discriminate recent infections from long-
standing ones using a single serum sample [3-5]. Their
development was based on the dynamics of the humoral
immune response during the post-seroconversion phase
o fH I Vi n f e c t i o n ,a n dr e l i e so nt h em o d i f i c a t i o n so f
early HIV-1 antibodies over time during the early phase
of the infection [6-8]. TRI are likely able to identify HIV
infections that occurred within 5-7 months before the
test with an overall median sensitivity of 88.8% (range
42.3-100%) and a median specificity of 86.8% (range
49.5-100%) [9], and some developed countries have
implemented surveillance with TRI [10-16] either at a
regional or national level. However, identifying recent
infections does not directly provide an estimate of the
incidence of HIV infection because persons who have
recently been infected can delay the testing and are not
necessarily tested in the first months after infection.
Karon et al. proposed a statistical model combining
HIV/AIDS surveillance data with TRI and testing history
that provided estimates of incidence of HIV infection in
t h eU S[ 1 6 , 1 7 ] .A n o t h e rs t u d yf o l l o w i n gas i m i l a r
approach provided incidence estimates for France [18].
In Lazio, a region located in central Italy including the
metropolitan area of Rome (almost six million inhabi-
tants), a combined surveillance of HIV and AIDS cases
has been active since 1985, [19] and since 2004, a TRI is
performed in a substantial percentage of new HIV diag-
noses through a multicentre study [20]. The test used to
detect recent infections is based on measuring the Avid-
ity Index (AI) of the HIV-1 specific antibodies which
s h o wal o wa v i d i t yf o rt h ea n t i g e ni nt h ee a r l yp h a s eo f
the infection [21-23]. It can be performed by an auto-
mated enzyme immunoassay for antibodies to HIV, it is
not expensive and has been shown to identify recent
HIV infections with good accuracy [22-25].
The objective of this study was to provide an estimate
of the incidence of HIV infection in this Italian region
b yu s i n gd a t ap r o v i d e db yt h er o u t i n es u r v e i l l a n c es y s -
tem and TRIs, using the method proposed by Karon et
al. [17].
Methods
The regional surveillance system of HIV and AIDS
diagnosis of the Lazio region
Although a national HIV surveillance system was not
implemented in Italy until 2009, in Lazio region, a man-
datory Regional Surveillance System of HIV infections -
based on the anonymous notification of every HIV diag-
nosis by public and private laboratories and blood
banks- has been established since 1985 [19]. HIV diag-
nosis is defined as a positive result on two consecutive
assays for HIV antibodies performed with commercially
available immunoenzymatic tests and confirmed by a
positive Western blot.
For each individual diagnosed with HIV, laboratories
fill a form with some personal identifying data [i.e., gen-
der, date (i.e., day, month and year) and municipality of
birth (country if born outside Italy) but not surname
and name]. Then the form is sent to the regional AIDS
units where the test result is given to the patient, and
other information (i.e., risk factors, date of last docu-
mented negative test when available) are collected dur-
ing the post-test counselling. All information are finally
collected and analysed at regional level.
In order to identify multiple tests of the same subject,
a linkage procedure, based on gender, date and munici-
pality of birth is routinely performed on the HIV diag-
nosis reports. This generates a file of newly diagnosed
HIV infection which is periodically updated. It is of note
that this procedure can identify different individuals
with the same gender, date and municipality of birth.
However, when we simulated the specificity of this com-
bination of information, using the National AIDS regis-
try (see below for description), that collects all the
personal identifying data for more than 60,000 cases, we
found around 1 duplicate every 2,000 AIDS cases (i.e.,
0.5 per 1,000). To ensure confidentiality, this file is pro-
tected by safety procedures and can only be accessed for
the purpose of surveillance.
Since 1985, following the indications of the Italian
AIDS registry, in Lazio Region AIDS diagnoses are
reported mandatorily. The case definition refers to the
European definition. Complete identifying personal data
are given in the form used and are routinely linked to
t h eH I Vd i a g n o s e su s i n gal i n k a g ep r o c e d u r eb a s e do n
gender, date and municipality of birth. The combination
of the two surveillance systems is called the Regional
Surveillance System of HIV and AIDS (RSS).
I nt h i ss t u d yw es e l e c t e da l ln e w l yd i a g n o s e dH I V
infections identified in the period from 2004-2008.
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The SENDIH (Studio Epidemiologico Nuove Diagnosi
Infezione HIV-1) is a multicentre study which started in
2004. Characteristics and methods of the study have
been previously described [20]. Briefly, the study collects
the following information on newly diagnosed adults
with HIV infection from 13 regional counselling and
testing sites of the Lazio region: demographic data (age,
gender, nationality, transmission category), date of last
HIV documented negative test, clinical and laboratory
data at diagnosis (including the presence of AIDS defin-
ing conditions, diagnosis of primary HIV infection,
HIVRNA measurement, and CD4 cell count), and, after
the individual has provided written informed consent,
behavioural data. The study was approved by the ethics
committee at the L. Spallanzani National Institute of
Infectious Diseases, and all enrolled individuals provided
written informed consent.
Linkage procedure between RSS and SENDIH
Given that neither RSS nor SENDIH collect complete
identifying personal data, each centre participating in
the SENDIH study was asked to send a file in which
there was a record for each diagnosis containing both of
the anonymous codes used for the RSS and the SEN-
DIH. The data were then combined using these files.
Definitions of recent and non recent infection
Only individuals enrolled in SENDIH study could have
been classified as having recent or long-standing infec-
tion. Recent infection identification was based on three
different criteria: 1) if an individual had a documented
negative HIV antibody test performed within 6 months
before HIV diagnosis; 2) if he/she had laboratory evi-
dence of HIV seroconversion at the time of diagnosis [i.
e., presence of HIV RNA or HIV p24 antigen with
simultaneous negative/indeterminate HIV antibody test-
ing (HIV-1/2 ELISA and Western Blot)]; 3) an AI <
0.80. To save laboratory resources, when one of the first
two criteria is met, the AI is not performed because the
individual is considered as having AI < 0.80.
An AI of HIV antibodies test was performed only if a
serum sample was available within 2 months after the
initial diagnosis, if the patient had a CD4 count ≥ 20
cells/μL and was clinical-AIDS-free. Moreover, since
early treatment was found to affect the evolution of HIV
antibody avidity [23], in newly diagnosed individuals
who started anti-retroviral therapy, AI was not
performed.
The AI of antibodies is calculated by an automated
anti-HIV enzyme immunoassay (EIA), the AxSYM HIV
1/2gO (Abbott Diagnostics Division, Delkenheim, Ger-
many), according to a procedure already described by
Selleri [23]. An AI lower than 0.80 was selected to
define a recent infection because identified as threshold
with the highest accuracy (area under the receiver oper-
ating curve: 0.958) corresponding to a sensitivity of
93.0% and a specificity of 98.5% [26]; this threshold was
found to be associated with a mean window period of
202 days (standard error: 18.4 days) [27].
Conversely, patients were classified as having non-
recent infection if they had an AI ≥ 0.80.
Incidence estimate of HIV infection
To estimate the regional incidence of HIV infection, we
used the model proposed by Karon et al. [17] that
accounts for the effect of testing practices on the num-
ber of persons detected as being recently infected.
According to this method, incidence is estimated as
the number of persons detected as being recently
infected divided by the estimated probability of being
detected as recently infected during the period of inter-
est. The incidence estimator is:
I = r/(p1
∗p2
∗p3),
where r is the number of recent infections detected, p1
represents the estimated probability of having a HIV test
within one year after infection (in brief it represents the
population testing behaviour), which is different for
individuals having a previous negative HIV test (defined
as repeat testers) and for individuals at their first HIV
test (new testers); p2 is the percentage of persons with a
newly reported HIV infection that had a TRI result; and
p3 is the probability of being classified as recently
infected, given a sample obtained at most one year after
infection.
Incidence of HIV infection was firstly estimated using
original data, assuming that the testing history data and
the AI results are missing completely at random. How-
ever, in a logistic regression model, significant predictors
(p < 0.001) of missing testing history information were
transmission category (three categories: MSM, IDU and
heterosexual contacts) and type of diagnosis (four cate-
gories: AIDS diagnosis, (at HIV or within six months
from HIV diagnosis), recent infection, non recent infec-
tion and HIV diagnosis AIDS-free with no criterion
available for defining recent infection), while significant
predictors (p < 0.001) of missing AI results were trans-
mission category, nationality (two categories: Italians
and non-Italians), and history of previous HIV testing
(two categories: Yes or No).
We then assumed that data on testing history and the
AI results were missing at random and missing data
were estimated by a two stage multiple imputation
procedure.
First, history of previous HIV testing based on trans-
mission category and type of diagnosis was imputed; at
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negative test, time delay between the two tests was
imputed using a linear regression model based on trans-
mission category and type of diagnosis as described
above and 5 datasets were generated. Second, the AI
results based on transmission category, nationality and
history of previous HIV testing were imputed and 4
datasets were imputed from those obtained at the first
stage (20 datasets in total).
For the original data and for each generated dataset
with no missing information, for repeat testers, p1
RT was
estimated as the mean inverse inter-test time for repeat
testers having a known last negative test date. For new
testers, p1
NT was estimated considering the proportion
of HIV infections diagnosed at the AIDS stage and the
distribution of the AIDS incubation periods, correspond-
ing to a median incubation time of 8 years between
infection and AIDS [28]. We used the US Centers for
Disease Control and Prevention AIDS case definition
[29] which is based on the presence of an AIDS defining
illness or a CD4 count < 200 cells/μL.
When estimating the incidence of HIV infection with
original data, p2 was estimated separately for repeat and
new testers; since p2 represents the probability that a
person diagnosed with HIV had a TRI that could result
in being classified as recent, p2 is estimated not consid-
ering persons with an initial diagnosis of AIDS or who
develop AIDS within 6 months of their HIV diagnosis.
When using the generated dataset with no missing
information p2 is one.
For p3, a mean window period for an AI < 0.80 of 202
days was considered [27]. We assumed that also patients
not tested with AI but identified as recently acquired
infections with the other criteria have an AI < 0.80.
For each dataset, the total incidence estimate was then
the sum of the estimated incidence for new testers,
INT =r NT/(p1
NT p2
NTp3)
and the estimated incidence for repeat testers,
IRT =r RT/(p1
RT p2
RTp3).
Variances and 95% confidence intervals reported were
calculated using the method recently proposed by Car-
negie [30].
For the imputed datasets, the estimates reported are
the mean of the 20 values obtained, while the lower and
the upper bound of the 95%CI were assumed to be
respectively the minimum of the lower bound and the
maximum of the upper bound, among the 20 estimates.
Estimates were stratified by calendar year, gender,
transmission category and nationality (i.e., Italian, non-
Italian).
To estimate incidence rates (overall or stratified by
calendar year or gender), we used annual estimates of
the population aged 15 years old or more residing in the
region of Lazio from the National Bureau of Census
http://www.demo.istat.it. The number of injecting drug
users were obtained using the prevalence of heroin
users in Italy from 2004-2008 estimated by the Eur-
opean Monitoring Centre for Drugs and Drug Addic-
tion, corrected by the proportion of injecting subjects
[31]. The estimated size of the non-national population
living in Lazio, including documented and non-docu-
mented immigrants, was obtained from the Dossier Sta-
tistico Caritas/Migrantes [32]. The number of men who
have sex with men was calculated as 3.1% of males aged
18-70, based on the results of a survey on sexual beha-
viours recently conducted in Italy [33].
Analyses were done with R software version 2.12 [34].
In particular package mi [35] was used for multiple
imputation and package hivi [30] was used to compute
95% confidence intervals of estimates.
Results
During the period 2004-2008, 3,633 new HIV diagnoses
were reported to the RSS within the end of 2010 (Table
1). Among them, 2,170 (60%) were diagnosed in SEN-
DIH sites. Individuals diagnosed in SENDIH were more
frequently men (79% vs. 70% in the non-SENDIH),
MSM (53% vs. 26%) and less frequently heterosexuals
(38% vs. 63%); no difference was observed by age and
for the percentage of IDU and foreigners. Of the 3,633
HIV diagnoses, 886 (24.4%) were classified as having
AIDS according to the CDC definition (of whom 69.4%
had a CD4 count < 200 cells/μL and no AIDS-defining
illness) and a further 512 (14%) were classified as long-
standing infections based on AI results. Two hundred
ninety (8%) individuals were classified as recent
Table 1 New HIV diagnoses by type of diagnosis and
information on a previous negative HIV test; Lazio, Italy,
2004-2008
Ever Tested HIV Negative?
Yes No Unknown Total
AIDS* within 6 months of HIV
diagnosis
19 65 100 184
AIDS* diagnosis at HIV diagnosis 102 324 276 702
HIV diagnosis, non-recent infection 278 194 40 512
HIV diagnosis, recent infection 190 55 45 290
HIV diagnosis, no test for recent
infection
201 177 1,567 1,945
Total 790 815 2,028 3,633
*Diagnoses at the AIDS stage were considered as non-recent regardless of
avidity index results. AIDS definition used: clinical AIDS or CD4 count < 200
cells/μL
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on AI results, 30% had a documented negative HIV test
in the previous 6 months, while the remaining 18% had
laboratory evidence of HIV seroconversion. One thou-
sand-nine-hundred-forty-five individuals (53.5% out of
the total, 34% out of those diagnosed in SENDIH sites)
were AIDS-free at the time of diagnosis of HIV but no
criterion to establish a recent infection was available.
Information about the history of previous HIV testing
was available for 44.2% of all cases: the proportion of
recent infection was 32.2% and 8.6% among classifiable
patients with and without a previous HIV test,
respectively.
After the multiple imputation procedure, overall, dur-
ing the period 2004-2008 we estimated 5,465 new infec-
tions in the region of Lazio (95%CI: 4,538-6,461) with
an average of 1,099 (23.8 per 100,000) estimated infec-
tions per year (Table 2).
The number of newly diagnosed cases per year was
q u i t es t a b l ed u r i n gt h es t u d yp e r i o d( a na v e r a g eo f7 2 3
new diagnoses per year, range 682-786) as it was the
number of estimated identified recent infections, except
for a peak observed in 2006 (Table 3). The estimated
infections per year varied greatly, ranging from a mini-
mum of 952 (19.9 per 100,000) in 2008 to a maximum
of 1,223 (26.8) in 2006 (Table 3).
When data were analyzed according to transmission
category (Table 4), the higher number of new diagnoses
was observed among heterosexual contacts (48.6% of the
total diagnoses) followed by MSM (41.9%). The highest
estimated number of identified recent infections was
among MSM (440 out of a total of 921 estimated as
identified during the study period, 48%) and in this
group there was a lower proportion of AIDS cases. The
highest number of new HIV infections was estimated to
have occurred among heterosexual contacts (2,599, 47%
out of the total), followed by MSM (2,208, 40%) and by
IDU (763, 13%).
With respect to gender and place of birth (Table 5),
men account for 76% of the new diagnoses and persons
born in Italy for 67%, respectively; the estimated percen-
tage of new diagnoses classified as recent infections
tended to be higher in men than in women and in those
born in Italy compared to foreign born individuals. The
number of new infections estimated for men was
approximately three times the number estimated for
women, and cases estimated for Italians were slightly
more than twice of those estimated for non-Italians
(Table 5).
Table 6 shows the estimated incidence rates in some
sub-groups (i.e., MSM, IDU, and non-Italians) by calen-
dar year. Compared to estimates reported for the gen-
eral population, on average, these rates are 30 times
higher in MSM, 40 times higher for IDU and 3 times
higher for non-Italians. Time trends in incidence for
MSM and non-Italians were similar to the overall trend,
while a constant decreasing trend was observed for IDU.
Discussion
During its first decade, the HIV epidemic in Italy was
predominantly characterized by infections linked to
intravenous drug use followed by those occurring
among MSM. In this study we show that during the
third decade of the epidemic, the majority of new HIV
infections in an Italian region can be estimated to occur
among heterosexual individuals. The HIV epidemic
however, continues to disproportionately affect MSM
and IDU. The overall estimated incident rates estimated
for the period from 2004-2008 are of the same order of
magnitude of those estimated for the 1990s, when the
Table 2 Parameter estimates, incidence estimates and 95% confidence intervals (based on both the original and
imputed data), Lazio, Italy, 2004-2008
Original data Imputed data
†
Repeat testers New testers Repeat testers New testers
r 190 55 620 301
p1 0.522 0.136 0.398 0.205
p2 0.696 0.585 1 1
Incidence estimate 946 1,250 2,818 2,647
(95% CI) (857-1,035) (966-1,534) (2,305-3,426) (1,739-3,593)
Diagnoses 790 815 1,646 1,987
Total incidence estimate (95% CI) 4,968
(4,356-5,441)
5,465
(4,538-6,461)
Estimated incidence rate* 21.1 23.8
* per 100,000 person-years; estimates refer to the mean population (aged 15 or older) in the region of Lazio during the period 2004-2008.
†mean values from 20 imputations.
P3 = 202/365.25 = 0.553.
CI, Confidence Interval.
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culation methods) was stabilizing after an initial peak
[36].
This is the first study that provides recent estimates of
HIV incidence in an Italian region. The last estimates
reported for the region of Lazio referred to 1992 with
an estimate of around 2,000 new infections from a
dynamic model [37]; in contrast, by using a back-calcu-
lation model, Bellocco et al. [38] estimated only 2500-
3000 infections in Italy during 1994, corresponding to
around 300-350 infections in Lazio region (based on the
assumption that Lazio region has quite constantly
accounted for 12% of the Italian AIDS cases each year
and that this percentage holds also in the new HIV
infections [39]). According to our estimates, in the per-
iod from 2004-2008 there was an average of around
1,099 infections per year. Although it is difficult to com-
pare our results with previous estimates, the mean num-
ber of infections estimated for 2004-2008 remains
surprisingly high.
There are no data available to provide a national esti-
mate of HIV incidence by using this method. However,
o nt h eb a s i so fo u rr e s u l t si tw o u l db ep o s s i b l et op r o -
vide a rough extrapolation of the expected number of
new infections in the country, since HIV diagnosis and
AIDS incidence in Lazio and the rest of Italy have simi-
lar temporal trends and similar characteristics in terms
of gender, age and risk groups, [39] and given that there
is free offer of treatment for infected persons in the
whole country. In fact, considering that the region of
Lazio has quite constantly accounted for 12% of the Ita-
lian AIDS cases each year, [39] and considering a mean
estimated number of infections of around 1,099 cases
each year in Lazio region, we could roughly estimate
around 9,100 new infections each year in the entire
country, which corresponds to an estimated incidence of
around 15 per 100,000.
Our incidence estimates generally varied by calendar
year but there was no specific trend. While the peak
was estimated in 2006, stratified analyses showed similar
results in each sub-group except for injecting drug users
for whom there was a clear decline of the estimated
recent infections in the period from 2004-2008.
The statistical model used in this paper has been pre-
viously applied in the US and in France. Incidence esti-
mates of 19.0 per 100,000 were obtained for the US [40]
and of 17 per 100,000 for France, both in 2008 [18];
these estimates are similar to those obtained in the
region of Lazio in the period 2004-2008.
Estimates of incidence rates by risk group provided
important information about the HIV epidemic in our
region. Regarding drug injection, the estimated number
of new infections related to this behaviour had a
decreasing trend during the period from 2004-2008, and
new infections related to this behaviour represented
approximately 14% of the overall cases estimated during
the study period. However, in 2008 the estimated inci-
dence rate was around 200 per 100,000, suggesting that
Table 3 Estimates of HIV incidence infections per calendar year, region of Lazio, Italy, 2004-2008
Year of
diagnosis
Newly diagnosed HIV
infections
Identified Recent Infections
N(%)*
Estimate
infections
95% Confidence
Interval
Estimated Incidence
rate**
2004 760 184 (24) 1,144 843 – 1,516 25.5
2005 695 185 (27) 1,190 892 – 1,567 26.2
2006 786 216 (27) 1,223 925– 1,636 26.8
2007 710 169 (24) 982 719 – 1,328 20.8
2008 682 167 (24) 952 625– 1,229 19.9
Total 3,633 921
* mean values from 20 imputations;% refers to the total of new diagnoses of each year
** per 100,000 person-years; estimates refer to the population (aged 15 or older) in the region of Lazio on January 1
st of each year
Table 4 Estimated new HIV infections, region of Lazio, Italy, 2004-2008, by transmission category (mean values from
20 imputations)
Heterosexual contacts MSM IDU
Total newly diagnosed HIV infections 1,765 1,523 345
Identified recent infection (%)* 371 (21) 440 (29) 110 (32)
Non-recent infection (%)* 920 (52) 765 (50) 141 (41)
AIDS case (%)* 474 (27) 318 (21) 94 (27)
Total incidence estimate (95% CI) 2,599
(1,930-3,386)
2,208
(1,641-2,689)
763
(476-1,059)
*% refers to the total number of diagnoses in each group
MSM, Men who have Sex with Men; IDU, Injecting Drug Users; CI, Confidence Interval
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who accounted for almost 40% of estimated infections,
had an alarmingly high incidence rate that was around
or above 500 per 100,000 in each year of the study.
These results are consistent with those reported in
France [18], where IDU and MSM were found to be dis-
proportionately affected by the HIV epidemic, under-
scoring the urgent need to reinforce the prevention
interventions that are targeted to these groups.
In this study we did not attempt to provide an esti-
mate of the incidence rates in heterosexuals, given the
wide heterogeneity of this group. Specific surveys are
needed to provide an estimate of heterosexuals at high
risk of HIV infection among whom incidence rates may
be very high, as suggested by a recent study conducted
in the US [41]. It is interesting to note that the higher
number of infections was estimated among heterosex-
uals while the number of diagnosed HIV infections clas-
sified as recent infections was higher among MSM. This
is likely due to the different testing behaviour of these
two groups, [42,43] and should be kept in mind when
interpreting the results of observational studies that
monitor the characteristics of recently acquired HIV
infections. Furthermore, we should also consider that
there is potential misclassification of MSM as heterosex-
ual contact [44].
Although these results may be relevant to understand-
ing recent trends of HIV epidemic in a low incidence
country, several limitations should be considered.
The criteria used to define recent/non-recent infection
are available only for persons diagnosed in SENDIH
sites, and we assumed that incidence risk is the same
for persons diagnosed in SENDIH and non-SENDIH
sites. We assumed that individuals with missing infor-
mation are missing at random and under this hypothesis
the multiple imputation should have reduced potential
bias in our estimates.
Table 5 Estimated new HIV infections, region of Lazio, Italy, 2004-2008, by gender and nationality (mean values from
20 imputations)
MEN WOMEN ITALIANS NON ITALIANS
Total newly diagnosed HIV infections 2,727 906 2,374 1,259
Identified recent infection (%)* 715 (26) 206 (23) 640 (27) 281 (22)
Non-recent infection (%)* 1,319 (49) 507 (56) 1,139 (48) 687 (55)
AIDS case (%)* 693 (25) 193 (21) 595 (25) 291 (23)
Total incidence estimate (95% CI) 4,197
(3,373-4,978)
1,280
(875-1,774)
3,773
(2,886-4,617)
1,703
(1,159-2,210)
*% refers to the total number of diagnoses in each group
CI, Confidence Interval
Table 6 Estimated new HIV infections and incidence, region of Lazio, Italy, 2004-2008, by transmission category and
nationality
Year Estimated infections*(95% CI) Estimated population size§ Estimated incidence rate**
MSM 2004 466 (267-714) 55,853 834
2005 488 (335-676) 56,479 864
2006 506 (292-714) 56,641 893
2007 352 (229-504) 58,596 601
2008 408 (238-561) 59,043 691
IDU 2004 216 (83-350) 15,784 1,368
2005 195 (59-400) 11,752 1,659
2006 158 (64-298) 12,666 1,247
2007 112 (8-215) 13,286 843
2008 74 (6-181) 12,818 577
NON-ITALIANS 2004 285 (143-420) 389,920 73
2005 389 (172-553) 418,823 93
2006 411 (211-683) 500,007 82
2007 331(144-509) 480,700 69
2008 292 (128-480) 450,151 65
* mean values from 20 imputations
§Population size estimates on January 1
st of each year; aged 18-70 years for MSM, 15-64 for IDU
**Per 100,000 person-years
MSM, Men who have Sex with Men; IDU, Injecting Drug Users; CI, Confidence Interval
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Page 7 of 10We combined three different criteria to define indivi-
duals with recent infection (i.e., an AI < 0.80, a previous
documented negative test within 6 months, or labora-
tory evidence of recently acquired infection). In the
model, we assumed that those identified as recent infec-
tion with the last two methods should have resulted
with an AI < 0.80 if tested. Thus, it was reasonable to
compute, also in this case, the incidence estimator as
proposed by Karon. It is possible that some recent infec-
tions established with criteria other than AI, would have
had an AI ≥ 08 and then classified as non-recent, but in
this case we improved the sensitivity of the AI.
Other possible biases were described in detail in the
article of Karon et al. [17] and these could also have
biased our estimates. Among them, the AI test could
have partly misclassified recent/non-recent infection
because the accuracy of this test is not one, as assumed
by the method. With regard to the reporting delays of
HIV diagnoses, we can fairly exclude delays, since the
period of interest was 2004-2008, the data were col-
lected until the end of 2010 and the region considered
is small.
The model assumes that the HIV test date is indepen-
dent of the infection date for new testers, while for
repeat testers it assumes that the risk of infection is
constant between the last negative and first positive test
date. Consequently the number of recent infections and
thus incidence could be overestimated in people seeking
HIV testing because of seroconversion symptoms or
recent exposure. This issue could be addressed taking
into account the reason for testing.
The history of testing and results of a TRI were not
available for a significant proportion of new diagnoses.
Preliminary analyses showed that results are strongly
dependent on some parameters such as the window per-
iod of TRI used, the percentage of those with unknown
testing history and the percentage of those without TRI
result. We partly addressed this limit using multiple
imputation that permits to correct the bias for missing
at random information. Collecting information about
HIV testing history and extending TRI to all new diag-
noses reported to the regional surveillance system could
improve the estimates limiting the effect of other source
of bias.
Reliability of incidence estimates in specific subpopu-
lations could be also affected by the accuracy of the sub-
population’s size, such as IDU and MSM.
Conclusion
In conclusion, this study combined surveillance data
with TRI to provide an estimate of the incidence of
HIV infections in recent years in an Italian region.
These estimates suggest that the transmission of HIV
i n f e c t i o ni nt h er e g i o no fL a z i or e m a i n sf r e q u e n ta n d
interventions for prevention should be considered. In
order to improve HIV incidence estimates, public
health departments should initiate programs to
increase the percentage of TRIs performed and other
regions should incorporate TRI results into their sur-
veillance systems.
Abbreviations
AI: Avidity index; AIDS: Acquired immune deficiency syndrome; CI:
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drug user; MSM: Men who have sex with men; TRI: Test for recent infection.
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